Lineage Announces Appointment of General Counsel
September 01 2021 - 8:00AM
Business Wire
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX),
a clinical-stage biotechnology company developing allogeneic cell
therapies for unmet medical needs, today announced that it has
appointed George A. Samuel III as Lineage’s General Counsel and
Corporate Secretary. Mr. Samuel will lead the Company’s legal
operations, bringing extensive corporate, transactional,
intellectual property and commercial expertise which spans nearly
15 years across the life sciences and technology sectors as well as
in private practice.
“We are pleased to welcome George to our leadership team and
look forward to his contributions as we build Lineage into a
leading cell therapy and cell transplant company,” stated Brian M.
Culley, Lineage CEO. “George’s diverse experience across legal and
other operational areas will be invaluable as we continue to
execute on our clinical development plans. In particular, his
transactional successes in business development and his
intellectual property experience will be key resources as we
evaluate partnership opportunities and expand collaborations for
our OpRegen, OPC1 and VAC2 programs and work to unlock additional
value from our extensive intellectual property portfolio.”
“I am looking forward to joining this dynamic and experienced
team by leading Lineage’s legal operations at this exciting and
transformative time,” stated George A. Samuel III. “The field of
cell therapy is undergoing rapid growth and I’m delighted to have
this opportunity to contribute to it.”
Prior to joining Lineage, Mr. Samuel most recently served as
Director, Senior Counsel for Lytx, Inc., where he managed the
commercial legal operations for an international video telematics
SaaS company. Prior to that, Mr. Samuel served as VP, General
Counsel and Corporate Secretary for Cardiff Oncology, Inc.
(formerly known as Trovagene, Inc.), a clinical-stage biotechnology
company focused on developing treatments in oncology. While at
Cardiff Oncology, he advised on strategic, business development and
operational decisions; oversaw capital raising efforts, regulatory
compliance as well as SEC reporting; and managed intellectual
property, including technology transfer and licensing. Mr. Samuel
has also practiced corporate law at major law firms, including DLA
Piper LLP and Cooley LLP, where he served as outside counsel to
public and private companies in a variety of commercial
transactions. Mr. Samuel received a J.D. from Columbia University
School of Law, and a B.A. in Philosophy from Tufts University and
is a member of the State Bar of California and New York.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology
company developing novel cell therapies for unmet medical needs.
Lineage’s programs are based on its robust proprietary cell-based
therapy platform and associated in-house development and
manufacturing capabilities. With this platform Lineage develops and
manufactures specialized, terminally differentiated human cells
from its pluripotent and progenitor cell starting materials. These
differentiated cells are developed to either replace or support
cells that are dysfunctional or absent due to degenerative disease
or traumatic injury or administered as a means of helping the body
mount an effective immune response to cancer. Lineage’s three
allogeneic (“off-the-shelf”) clinical programs are in markets with
billion dollar opportunities: (i) OpRegen®, an investigational
retinal pigment epithelium transplant therapy in Phase 1/2a
development for the treatment of dry age-related macular
degeneration, a leading cause of blindness in the developed world;
(ii) OPC1, an investigational oligodendrocyte progenitor cell
therapy in Phase 1/2a development for the treatment of acute spinal
cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy
platform for immuno-oncology and infectious disease, with
investigational immunotherapy VAC2 currently in clinical
development for the treatment of non-small cell lung cancer. For
more information, please visit www.lineagecell.com or follow the
Company on Twitter @LineageCell.
Forward-Looking Statements
Lineage cautions you that all statements, other than statements
of historical facts, contained in this press release, are
forward-looking statements. Forward-looking statements, in some
cases, can be identified by terms such as “believe,” “may,” “will,”
“estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,”
“could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,”
“contemplate,” project,” “target,” “tend to,” “look forward to” or
the negative version of these words and similar expressions. Such
statements include, but are not limited to, statements relating to
Lineage’s ability to become a leading cell therapy and cell
transplant company, to expand collaborations for its product
candidate programs, and to unlock value from its intellectual
property portfolio, and the commercial potential for cell therapy
products. Forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause Lineage’s
actual results, performance or achievements to be materially
different from future results, performance or achievements
expressed or implied by the forward-looking statements in this
press release, including risks and uncertainties inherent in
Lineage’s business and other risks discussed in Lineage’s filings
with the Securities and Exchange Commission (the SEC). Further
information regarding these risks, uncertainties and factors is
included under the heading “Risk Factors” in Lineage’s periodic and
other reports filed with the SEC, including Lineage’s most recent
Annual Report on Form 10-K and Quarterly Reports on Form 10-Q,
which are available from the SEC’s website. Lineage’s
forward-looking statements are based upon its current expectations
and involve assumptions that may never materialize or may prove to
be incorrect. All forward-looking statements are expressly
qualified in their entirety by these cautionary statements. You are
cautioned not to place undue reliance on forward-looking
statements, which speak only as of the date on which they were
made. Lineage undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210901005330/en/
Lineage Cell Therapeutics, Inc. IR Ioana C. Hone
(ir@lineagecell.com) (442) 287-8963
Solebury Trout IR Gitanjali Jain Ogawa
(Gogawa@soleburytrout.com) (646) 378-2949
Russo Partners – Media Relations Nic Johnson or David
Schull Nic.johnson@russopartnersllc.com
David.schull@russopartnersllc.com (212) 845-4242
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Apr 2023 to Apr 2024